CAS 1402820-62-5

General Information

Derived from needles of yew trees, cabazitaxel is prescribed for the treatment of patients with hormone-refractory prostate cancer (HRPC) that has spread to other parts of the body and was previously treated with a docetaxel-containing treatment regimen. It is used in combination with prednisone. HRPC is a prostate cancer that has become unresponsive to hormonal manipulation.Cabazitaxel is administered intravenously.


In 2010, the FDA approved cabazitaxel under the trade name Jevtana for use in combination with prednisone for treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen. It is produced through semi-synthesis, a chemical process that makes use of compounds derived from natural sources as starting material. Its precursor is extracted from the needles of various species of yew trees (Taxus species).

About the API

Systematic name (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate – propan-2-one (1
Trade name(s) Jevtana
Molecular Formula C45H57NO14.C3H6O
Molecular Weight 894.01 g/mol
Physical properties White to almost-white powder
Therapeutic category Oncology
Available formulations Injectables
Regulations Canada DMF Flag Canada DMF CEP Flag CEP EU DMF Flag EU DMF US DMF Flag US DMF